Statin's Coat of Many Colors Receives Yet Another Hue

Journal of the American Society of Nephrology

Volumn 15, Issue 4, 2004, Pages 1098-1100

  Goligorsky, Michael S ^a   Wang, Wenhui ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ACTIVATED POTASSIUM CHANNEL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STATINE DERIVATIVE;

ANTICOAGULATION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; PRIORITY JOURNAL; VASODILATATION; BLOOD VESSEL; HUMAN; NOTE;

BLOOD VESSELS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; POTASSIUM CHANNELS, CALCIUM-ACTIVATED;

EID: 1642400706     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000120180.56818.9E     Document Type: Editorial

References (22)

1. World Heath Organization: World Health Report. Geneva, World Heath Organization, 1998
2. Lindner A, Charra B, Sherrard D, Scribner B: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290: 697-701, 1974
3. Foley R, Parfrey P, Sarnak M: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: 112-119, 1998
4. Kannel W, Castelli W, Gordon T, McNamara P: Serum cholesterol, lipoproteins, and the risk of coronary heart disease. Ann Intern Med 74: 1-12, 1971
5. Kasiske B: Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 32: 142-156, 1998
6. Gotto A, Farmer J: Pleiotropic effects of statins: Do they matter? Curr Opin Lipidol 12: 391-394, 2001
7. Balk E, Lau J, Goudas L, Jordan H, Kupelnick B, Kim L, Karas R: Effects of statins on nonlipid serum markers associated with cardiovascular disease. Ann Intern Med 139: 670-682, 2003
8. Takemoto M, Liao J: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21: 1712-1719, 2001
9. Goldstein J, Brown M: Regulation of the mevalonate pathway. Nature 343: 425-430, 1990
10. Laufs U, LaFata V, Plutzky J, Liao J: Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 97: 1129-1135, 1998
11. Laufs U, Liao J: Posttranscriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273: 24266-24271, 1998
12. Rikitake Y, Kawashima S, Takeshita S: Antioxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 154: 87-96, 2001
13. Takemoto M, Node K, Nakagami H: Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 108: 1429-1437, 2001
14. Weitz-Schmidt G, Welzenbach K, Brinkmann V: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7: 687-692, 2001
15. Dimmeler S, Aicher A, Vasa M: HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 108: 391-397, 2001
16. Vasa M, Fichtlscherer S, Adler K: Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103: 2885-2890, 2001
17. Kuhlmann CRW, Gast C, Li F, Schafer M, Tillmanns H, Waldecker B, Wiecha J: Cerivastatin activates endothelial calcium-activated potassium channels and thereby modulates endothelial NO production and cell proliferation. J Am Soc Nephrol 14: 868-875, 2004
18. Schilling W: Effect of membrane potential on cytosolic calcium of bovine aortic endothelial cells. Am J Physiol 257: H778-H784, 1989
19. Vaca L, Licea A, Possani L: Modulation of cell membrane potential in cultured vascular endothelium. Am J Physiol 270: C819-C824, 1996
20. Goligorsky M, Li H, Brodsky S, Chen J: Relations between caveolae and eNOS: Everything in proximity and proximity of everything. Am J Physiol 283: F1-F10, 2002
21. Feron O, Dessy C, Desager J, Balligand J: HMG-CoA reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 103: 113-118, 2001
22. Kuhlmann CRW, Gast C, Li F, Sawamura T, Schafer M, Tillmanns H, Waldecker B, Wiecha J: Modulation of endothelial Ca-activated K channels by oxidized LDL and its contribution to endothelial proliferation. Cardiovasc Res 60: 626-634, 2003